Objective Response Rate of 92%: Heyuan Bio's CD19 CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma Published in Journal for ImmunoTherapy of Cancer

May 17, 2024 07:19 CST Updated 07:20

Juventas

Innovative Cell Therapy Drug Developer

May 17, 2024

eMedClub News

Recently, the international authoritative academic journal "Journal for ImmunoTherapy of Cancer》（IF=10.9) Published online a paper entitled "Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed refractory large B-cell lymphoma" research paper, Professor Dehui Zou and Professor Wenting Zheng from the Blood Disease Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) are the co-corresponding authors of the paper, confirming that autologous hematopoietic stem cell transplantation withCD19 CAR-TCell therapy (Juventas, Naciorl Injection) can be used in combination.Significantly ImproveRecurrent and Refractory LargeBCellular Lymphoma (r/r LBCL`) Patient`The success rate of salvage therapy is high, and the safety is good.

LargeBCellular lymphoma is an aggressive tumor with high heterogeneity, high malignancy, rapid disease progression, and a high mortality rate, posing a serious threat to patients' lives, approximately40%Left and Right Patients1Recurrent or refractory after line treatment. Recurrent refractory largeBCellular Lymphoma (r/r LBCL) remains a severe challenge in clinical treatment, chimeric antigen receptorTCell Therapy (CAR-T) Inr/r LBCLhas shown remarkable application prospects in the treatment.

This study is an investigator-initiated trial of autologous hematopoietic stem cell transplantation combined with Nalkio Cell Injection for the treatment of relapsed or refractory large...BCellular Lymphoma (r/r LBCL) Exploratory Clinical Study on the Safety and Efficacy of (NCT04690192), the researcher is Professor Dehui Zou's team from the Blood Disease Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences).

In this study, Juventas...25Exampler/r LBCLThe patient underwent autologous hematopoietic stem cell transplantation (HDT/ASCT) Combined with Najiolumab Injection Treatment.

June 14-15

IBI EXPO

Recommended Thematic Forums

(Swipe up and down to view more)

Scan the code

Limited Time Offer

Free Tickets

Hotline for Cooperation

18701871600 (Manager Wang)

15572286596 (Manager Yuan)

Effectiveness:The Best Objective Response Rate After Treatment Is92%, The complete remission rate is72%Median follow-up27months, median progression-free survival (PFS) and overall survival (OS) has not yet arrived,2The progression-free survival rate and overall survival rate at year were respectively62.3%And68.5%。

Safety:No ≥ was observed during the treatment period3Grade Cytokine Release Syndrome (CRS), only2Example (8%) Patients experience ≥3LevelCAR-TCell-Associated Encephalopathy Syndrome (CRES), all patients fully recovered after hormone treatment, and no unexpected adverse events were observed.

In addition, the study used flow cytometry to analyze cryopreserved peripheral blood mononuclear cell samples for evaluating the efficacy of Nacioranase (CNCT19) Injection Cell Infusion In Vivo Expansion Capability and Exhaustion Molecules (PD1、TIGIT) The proportion of expression was analyzed, suggesting that combination therapy can regulateCAR-TThe in vivo behavior of cells partially reveals the potential mechanism by which combination therapy can enhance efficacy.

Conclusion: The combination therapy of Naciorl Injection and autologous hematopoietic stem cell transplantation demonstrated significant efficacy, favorable safety, and the potential to promote.CAR-TIn vivo proliferation and effector differentiation of cells, reducingCAR-TCell exhaustion, forCAR-TA Strong New Piece of Evidence Emerges in the Exploration of Combination Therapy.

About Juventas

Juventas, founded in June 2018, has grown into a leading innovator in China's cell therapy industry, striving to become a globally leading biopharmaceutical company driven by cutting-edge cell and gene technologies. The company’s first core product, Yuan Ruida® (Nabti-Olone Cel Injection, CNCT19), was officially approved for marketing by the National Medical Products Administration in November 2023.This product is the first CAR-T drug in China's leukemia treatment field, and also the first fully self-innovated CD19 CAR-T drug in China.The company has deeply cooperated with top national institutions in China, building an international new drug R&D system centered on technical platforms such as CAR, iPSCs, and gene editing. It has over 10 pipeline products under research and development, covering diseases like hematological tumors, solid tumors, and autoimmune diseases.

2024 IBI EXPO Schedule Overview

Scan the code

Limited Time Offer

Free Tickets

References:

1.https://mp.weixin.qq.com/s/i-bBmYPPhc8VZ3uiCcTWuw

Statement and Copyright Notice

Disclaimer: This article aims to convey industry development information and explore the frontier progress of biomedicine. The content of the article represents the author's viewpoint, and does not represent the position of Eureka Biomedical, nor does it constitute any value judgment, investment advice, or medical guidance. If necessary, please consult a professional for investment or visit a regular hospital for medical advice.

DianDian "Share”、“Like"and"In View"，Give me a little recharge~"